Evaluating dyes for safer eye surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the mechanical properties of the internal limiting membrane (ILM) and the effectiveness of intraoperative dyes, specifically Brilliant Blue G (BBG) and Indocyanine Green (ICG), during chromovitrectomy procedures. The research aims to enhance the safety and efficacy of ILM removal, which is crucial for treating conditions like macular edema. By analyzing the performance of these dyes, the study seeks to identify modifications that could improve their utility while minimizing ocular toxicity. The study involves patients undergoing vitrectomy and utilizes data from deceased donor membranes for additional insights.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Over 18 Years of age
* No other chromovitrectomy in previous 6 months
* Only one of three vitaly dyes used intraoperatively (BBG, ICG or TB)

Exclusion Criteria:

* Previous chromovitrectomy during last 6 months
* Pregnant patients
* Patients under 18 years of age

Where it's running

• General Hospital Linz
  Linz, Austria Recruiting
• St. Gallen Hospital
  Sankt Gallen, Canton of St. Gallen, Switzerland Recruiting
• Oftacentro
  Paradiso, Canton Ticino, Switzerland Recruiting

Study contacts

• Principal investigator: Paul B Henrich, MD — Oftacentro, Lugano-Paradiso, Switzerland
• Study coordinator: Paul B. Henrich, MD, Ph.D.
• Email: henrich.oftacentro@hin.ch
• Phone: +41 91 9932727

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MK-8748 vs. aflibercept for diabetic macular edema

  This trial tests whether the investigational medicine MK-8748 can treat diabetic macular edema as well as the standard treatment aflibercept in adults with diabetes.

  Recruiting at 20 sites Phase 3 Merck Sharp & Dohme LLC · Long Beach, California and 19 other locations · NCT07705607

• MK-8748 vs aflibercept for diabetic macular edema

  This trial tests whether MK-8748 can treat diabetic macular edema as well as the standard treatment aflibercept in people with diabetes.

  Recruiting at 35 sites Phase 3 Merck Sharp & Dohme LLC · Gilbert, Arizona and 34 other locations · NCT07705555

• BI 1815368 for centre-involved diabetic macular edema.

  This study will test whether the oral medicine BI 1815368 can improve vision in adults with centre-involved diabetic macular edema and determine the best dose.

  Recruiting at 79 sites Phase 2 Boehringer Ingelheim · Phoenix, Arizona and 96 other locations · NCT06962839

• Evaluating KIO-104 for treating macular edema

  This study is testing a new treatment called KIO-104 to see if it can safely help people with macular edema improve their vision.

  Recruiting at 6 sites Phase 2 Kiora Pharmaceuticals, Inc. · Sydney, New South Wales and 5 other locations · NCT06825702

• Micropulsed laser treatment for macular edema in retinal dystrophies

  This study is testing a new type of laser treatment to see if it can help reduce swelling in the eyes of people with inherited retinal diseases.

  Recruiting Fondazione G.B. Bietti, IRCCS · Rome, RM · NCT05976139

• Treatment for diabetic retinopathy with MS-553

  This study is testing a new oral medication called MS-553 to see if it can improve vision and reduce swelling in the eyes of people with diabetic retinopathy.

  Recruiting at 3 sites Phase 1 MingSight Pharmaceuticals, Inc · Changsha, Hunan and 2 other locations · NCT04187443

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.